Patient infection/reactivation status and outcome
| Patient . | Indication . | Prior therapy . | Viral course after VST . | Status within first year . |
|---|---|---|---|---|
| P0123 | Adenovirus low-level viremia (<200 copies per mL) and positive upper respiratory tract | Cidofovir | Resolution (with brincidofovir) | Alive, GVHD resolved at 1 y |
| P0067 | CMV 2239 cells per mL | Foscarnet/cidofovir/ganciclovir | CMV viremia resolved by 6 mo but developed CMV retinitis 6 mo after infusion | Alive, CMV retinitis at 6 mo treated with third-party T cells and intravitreal ganciclovir with complete resolution, GVHD resolved at 1 y |
| P0039 | CMV low-level viremia (<1000 copies per mL) | Foscarnet/cidofovir/ganciclovir | Resolution | Leukemia relapse after 90 d, in remission after CAR T-cell therapy |
| P0035 | CMV low-level viremia (<1000 copies/mL) and positive stool | Foscarnet | Resolution (with valganciclovir) | Alive, quiescent GVHD on cyclosporine at 1 y |
| P2891 | CMV viremia (100 copies/mL) | Foscarnet, CMV immunoglobulin | Resolution (with ganciclovir + 2 additional CB-VST infusions) | Alive, GVHD resolved at 1 y |
| P3626 | EBV in bone marrow (3500 copies/mL) | Cidofovir for previous adenoviremia | Fivefold decline in bone marrow EBV at 5 mo, negative in blood at 1 y, no PTLD | Alive, MDS + monosomy 7 at <1 y resolved at 2 y. No GVHD, off immunosuppression at 1 y |
| P3457 | EBV viremia (109 copies/mL) | None | Persistent viremia but no PTLD | Died after second transplant for relapsed leukemia |
| P3010 | Prophylaxis | Ganciclovir prophylaxis | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3275 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3317 | Prophylaxis | Ganciclovir prophylaxis | No reactivation requiring therapy, no disease | Relapse/AML progression <1 y after HCT, deceased day +284. |
| P3531 | Prophylaxis | Valganciclovir prophylaxis | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3555 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, resolved GVHD at 1 y |
| P3923 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P0020 | Prophylaxis/past history of adenovirus in stool | Cidofovir | Adenovirus reactivation in stool at 3 wk and then blood 3 mo after VSTs; given second CB-VST infusion and continued with cidofovir | Alive, quiescent GVHD on cyclosporine at 1 y |
| Patient . | Indication . | Prior therapy . | Viral course after VST . | Status within first year . |
|---|---|---|---|---|
| P0123 | Adenovirus low-level viremia (<200 copies per mL) and positive upper respiratory tract | Cidofovir | Resolution (with brincidofovir) | Alive, GVHD resolved at 1 y |
| P0067 | CMV 2239 cells per mL | Foscarnet/cidofovir/ganciclovir | CMV viremia resolved by 6 mo but developed CMV retinitis 6 mo after infusion | Alive, CMV retinitis at 6 mo treated with third-party T cells and intravitreal ganciclovir with complete resolution, GVHD resolved at 1 y |
| P0039 | CMV low-level viremia (<1000 copies per mL) | Foscarnet/cidofovir/ganciclovir | Resolution | Leukemia relapse after 90 d, in remission after CAR T-cell therapy |
| P0035 | CMV low-level viremia (<1000 copies/mL) and positive stool | Foscarnet | Resolution (with valganciclovir) | Alive, quiescent GVHD on cyclosporine at 1 y |
| P2891 | CMV viremia (100 copies/mL) | Foscarnet, CMV immunoglobulin | Resolution (with ganciclovir + 2 additional CB-VST infusions) | Alive, GVHD resolved at 1 y |
| P3626 | EBV in bone marrow (3500 copies/mL) | Cidofovir for previous adenoviremia | Fivefold decline in bone marrow EBV at 5 mo, negative in blood at 1 y, no PTLD | Alive, MDS + monosomy 7 at <1 y resolved at 2 y. No GVHD, off immunosuppression at 1 y |
| P3457 | EBV viremia (109 copies/mL) | None | Persistent viremia but no PTLD | Died after second transplant for relapsed leukemia |
| P3010 | Prophylaxis | Ganciclovir prophylaxis | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3275 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3317 | Prophylaxis | Ganciclovir prophylaxis | No reactivation requiring therapy, no disease | Relapse/AML progression <1 y after HCT, deceased day +284. |
| P3531 | Prophylaxis | Valganciclovir prophylaxis | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P3555 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, resolved GVHD at 1 y |
| P3923 | Prophylaxis | None | No reactivation requiring therapy, no disease | Alive, no GVHD, off immunosuppression at 1 y |
| P0020 | Prophylaxis/past history of adenovirus in stool | Cidofovir | Adenovirus reactivation in stool at 3 wk and then blood 3 mo after VSTs; given second CB-VST infusion and continued with cidofovir | Alive, quiescent GVHD on cyclosporine at 1 y |
CAR, chimeric antigen receptor; HCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; PTLD, posttransplantation lymphoproliferative disorder.